FR167653, a p38 mitogen-activated protein kinase inhibitor, aggravates experimental colitis in mice

World Journal of Gastroenterology

Volumn 14, Issue 38, 2008, Pages 5851-5856

  Nishimura, Takashi ^a   Andoh, Akira ^a   Nishida, Atsushi ^a   Shioya, Makoto ^a   Koizumi, Yuhsuke ^a   Tsujikawa, Tomoyuki ^a   Fujiyama, Yoshihide ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Cytokine; Experimental colitis; Inflammatory bowel disease; p38; Tumor necrosis factor

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; CYTOKINE; DEXTRAN SULFATE; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; DIFFERENTIATION ANTIGEN; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; EXPERIMENTAL INFECTION; GENE EXPRESSION; HISTOPATHOLOGY; HOST RESISTANCE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; COLON; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HOSPITALIZATION; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MOUSE; PATHOLOGY; TIME;

ANIMALS; ANTIGENS, DIFFERENTIATION; BODY WEIGHT; CD4-POSITIVE T-LYMPHOCYTES; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63449088019     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.5851     Document Type: Article

References (32)

1. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 2008; 43: 1-17
2. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007; 42: 16-25
3. Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep 2007; 9: 497-507
4. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40
5. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773: 1358-1375
6. Cook R, Wu CC, Kang YJ, Han J. The role of the p38 pathway in adaptive immunity. Cell Mol Immunol 2007; 4: 253-259
7. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002; 168: 5342-5351
8. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122: 7-14
9. Waetzig GH, Schreiber S. Review article: mitogenactivated protein kinases in chronic intestinal inflammation - targeting ancient pathways to treat modern diseases. Aliment Pharmacol Ther 2003; 18: 17-32
10. Wysk M, Yang DD, Lu HT, Flavell RA, Davis RJ. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Natl Acad Sci USA 1999; 96: 3763-3768
11. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ, Flavell RA. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J 1999; 18: 1845-1857
12. Yoshino O, Osuga Y, Koga K, Hirota Y, Hirata T, Ruimeng X, Na L, Yano T, Tsutsumi O, Taketani Y. FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol 2006; 72: 85-93
13. Chan KL, Guo WH, Chan KW, Tam PK. FR167653 ameliorates intestinal allograft ischemic injury. Transplant Proc 2000; 32: 1643-1644
14. Aleshin A, Sawa Y, Ono M, Funatsu T, Miyagawa S, Matsuda H. Myocardial protective effect of FR167653; a novel cytokine inhibitor in ischemic-reperfused rat heart. Eur J Cardiothorac Surg 2004; 26: 974-980
15. Yao HW, Li J, Chen JQ. FR167653 attenuates murine immunological liver injury. World J Gastroenterol 2004; 10: 2267-2271
16. Wei YH, Li Y, Qiang CJ. Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats. Int Immunopharmacol 2004; 4: 1625-1632
17. Yamamoto N, Sakai F, Yamazaki H, Sato N, Nakahara K, Okuhara M. FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock. Eur J Pharmacol 1997; 327: 169-174
18. Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M. Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol 1996; 314: 137-142
19. Takahashi S, Keto Y, Fujita T, Uchiyama T, Yamamoto A. FR167653, a p38 mitogen-activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils. J Pharmacol Exp Ther 2001; 296: 48-56
20. Hato S, Urakami A, Yamano T, Uemura T, Ota T, Hirai R, Shimizu N. Attenuation of liver and lung injury after hepatic ischemia and reperfusion by a cytokine-suppressive agent, FR167653. Eur Surg Res 2001; 33: 202-209
21. Nishikori T, Irie K, Suganuma T, Ozaki M, Yoshioka T. Anti-inflammatory potency of FR167653, a p38 mitogenactivated protein kinase inhibitor, in mouse models of acute inflammation. Eur J Pharmacol 2002; 451: 327-333
22. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249
23. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987; 162: 156-159
25. Murphy E, Hieny S, Sher A, O'Garra A. Detection of in vivo expression of interleukin-10 using a semi-quantitative polymerase chain reaction method in Schistosoma mansoni infected mice. J Immunol Methods 1993; 162: 211-223
26. Yao HW, Yue L. Effect and mechanisms of FR167653, a dual inhibitor of TNF-alpha and IL-1, on BCG plus LPS inducedliver injury. Inflamm Res 2005; 54: 471-477
27. Takeyoshi I, Yoshinari D, Kobayashi M, Kurabayashi M, Morishita Y. A dual inhibitor of TNF-alpha and IL-1 mitigates liver and kidney dysfunction and improves survival in rat endotoxemia. Hepatogastroenterology 2005; 52: 1507-1510
28. Malamut G, Cabane C, Dubuquoy L, Malapel M, Derijard B, Gay J, Tamboli C, Colombel JF, Desreumaux P. No evidence for an involvement of the p38 and JNK mitogenactivated protein in inflammatory bowel diseases. Dig Dis Sci 2006; 51: 1443-1453
29. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002; 50: 507-512
30. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004; 18: 1550-1552
31. Karrasch T, Steinbrecher KA, Allard B, Baldwin AS, Jobin C. Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol 2006; 207: 809-815
32. Leghmari K, Bennasser Y, Tkaczuk J, Bahraoui E. HIV-1 Tat protein induces IL-10 production by an alternative TNF-alpha-independent pathway in monocytes: role of PKC-delta and p38 MAP kinase. Cell Immunol 2008; 253: 45-53